GLY-200

DRUG2 trials

Sponsors

Glyscend, Inc.

Conditions

ObesityType 2 Diabetes

Phase 2

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

CompletedNCT05478525

Glyscend, Inc.Type 2 Diabetes

Start: 2022-08-03End: 2023-03-14Updated: 2025-02-10

A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

CompletedNCT06259981

Glyscend, Inc.Obesity

Start: 2024-05-20End: 2024-10-23Updated: 2025-01-23

Related Papers

<scp>GLY</scp> ‐200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism2025-08-061 citations